provectus_logo.jpg
PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10
July 31, 2018 08:00 ET | Provectus Biopharmaceuticals Inc.
Ongoing Phase 1 basket study of PV-10 for cancers of the liver expanded to include single-center cohort of metastatic uveal melanoma patients Presentation of initial metastatic uveal melanoma data...
webprofile_barrett_am
Participants needed for brain injury research studies at Kessler Foundation
October 19, 2016 11:04 ET | Kessler Foundation
EAST HANOVER, N.J., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Kessler Foundation is recruiting study participants for multiple research programs aimed at improving cognition, mobility, and long-term outcomes...
Glycotex, Inc. Obtains Active IND From US Food and Drug Administration for GLYC-101 Wound Healing Compound
January 07, 2008 18:58 ET | Glycotex, Inc., Novogen Limited
ROCKVILLE, MD--(Marketwire - January 7, 2008) - Glycotex, Inc. announced today that it had obtained an active Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA)...
Research Indicates Synthetic Compound NV-52 May Be Useful in Treatment of Inflammatory Bowel Disease
November 13, 2007 08:04 ET | Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - November 13, 2007) - An article published in a recent edition of the peer review journal Expert Opinion, Vol. 16, No. 8, reveals the compound...
New Data on Novogen Oncology Pipeline to Be Released
October 23, 2007 08:05 ET | Novogen
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - October 23, 2007) - New data on the Novogen oncology pipeline compound NV-128 will be presented on October 23 at the annual AACR/EORTC/NCI...